| Similar Articles |
|---|
 |
The Motley Fool
June 17, 2004
Charly Travers |
No Heartburn for Santarus As a small company, Santarus is definitely going to have its hands full marketing the new heartburn drug Rapinex against some of the biotech giants.   |
The Motley Fool
October 7, 2004
Charly Travers |
Santarus Takes on Big Pharma Can this small drug company compete with the industry's giants? Santarus bolstered its marketing efforts with the signing of a very beneficial partnership with Otsuka America Pharmaceutical. |
The Motley Fool
January 20, 2006
Rich Duprey |
Generics Give Originators Heartburn Eisai, the Japanese manufacturer of an acid reflux remedy, sees a generic maker win FDA approval. What does this mean for investors? |
The Motley Fool
January 8, 2010
Brian Orelli |
Heartburn Relieved ... for Now AstraZeneca settles its patent dispute with Teva. |
The Motley Fool
April 1, 2004
Charly Travers |
Atrix Batting 1.000 Atrix Laboratories' drugs have breezed past the Food and Drug Administration. |
American Family Physician
July 15, 2002
Bruce T. Vanderhoff & Rundsarah M. Tahboub |
Proton Pump Inhibitors: An Update Proton pump inhibitors (PPIs) are one of the most commonly prescribed classes of medications in the primary care setting and are considered a major advance in the treatment of acid-peptic diseases. |
The Motley Fool
November 8, 2006
Brian Lawler |
Will Santarus Heal Investors' Heartburn? This pharma's fortunes will rise or fall on its single drug. In a few quarters, investors should be able see if this is worth their consideration. |
The Motley Fool
December 3, 2009
Brian Orelli |
I Love This Industry With double-digit gains, how could you not love the biotech industry? |
The Motley Fool
November 30, 2010
Brian Orelli |
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist. |
The Motley Fool
March 4, 2004
Brian Gorman |
Biotech Is Back Biotech financing is on a roll. But before you jump into the sector, learn some lessons from the past. Companies that enter the market earlier in the boom are better positioned than those that start later, and it's best to choose firms with late-stage drug candidates. |
The Motley Fool
April 8, 2004
Charly Travers |
Indevus' Big Score (Maybe) A small biotech company lands a potentially rich deal. |
American Family Physician
October 1, 2003
Heidelbaugh et al. |
Management of Gastroesophageal Reflux Disease This article summarizes an evidence-based approach to the cost-effective management of patients with GERD. |
Managed Care
December 2002 |
Generic Prilosec... Ready or not, here it comes A consortium of manufacturers has received FDA approval to launch a generic version of the huge-selling proton-pump inhibitor Prilosec (omeprazole). The launch is expected by the end of the year. How will MCO drug formularies react? Watch this space. |
Inc.
May 1, 2002
Kenneth Klee |
The Industry You Can't Afford to Miss After more than two decades of hype, hope, disappointment, and progress, the hundreds of mostly small, money-burning companies that make up the biotech industry are experiencing a decisive shift in their relationship with the giant, rich pharmaceutical companies... |
The Motley Fool
March 18, 2004
Brian Gorman |
The Drug Cost Conundrum While drug prices continue to climb, the public and its representatives in government are demanding cheaper pharmaceuticals. The industry is not likely to find cover in Medicare biotechnology. Instead, investors should look for drug makers that are finding ways to operate leaner and meaner. |
The Motley Fool
December 16, 2003
David Nierengarten |
Biotech's Next Phase It's been a great year for biotech, but don't count on a repeat in 2004. Here are some tips for evaluating biotechnology and pharmaceutical stocks. |
| Knowledge@Wharton |
The Benefits Are Mutual in New Wave of Biotech/Pharma Alliances The spat that erupted between pharma giant Bristol-Myers Squibb and biotech firm ImClone Systems over their partnership to develop a new cancer drug put the structure of alliances between discovery research firms and big drug makers under a microscope... |
The Motley Fool
June 22, 2010
Dave Mock |
A Big Upgrade for DepoMed This bullish call comes from more than just one analyst. |
CFO
Kris Frieswick |
Clinical Trials A new kind of pricing pressure puts pharmaceutical CFOs in an unfamiliar role: evangelist... |
The Motley Fool
May 12, 2004
Phil Wohl |
Mylan's Big Break? The maker of generic pimple cream wants to lead the pack. Can it? |
American Family Physician
November 15, 2003 |
Heartburn What is heartburn?... What causes heartburn?... Can heartburn be serious?... What can I do to feel better?... Will antacids get rid of heartburn?... etc. |
Bio-IT World
June 15, 2003
Bob Violino |
Northeast Region Massachusetts: University and Research Hub... Connecticut: Investing in Bio Facilities... New York: Biotech Empire State... New Jersey: Still Big Pharma Country... Pennsylvania: Life Sciences, a Keystone Industry |
